Recent News
Read ArticleDr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Rheumatoid Arthritis Faculty Panel Q&A
This expert panel from https://t.co/4UQlqwujiR 2026 brings together leading faculty to address real-world challenges in RA care, offering practical insights you can apply immediately in practice.
🎧 Listen here: https://t.co/LOiUuia852 https://t.co/REvpPJv0O8
Dr. John Cush @RheumNow ( View Tweet)
TRACE study in 90 active axSpA, biologic-naĂŻve, Rx w/ secukinumab 150 mg; @wk16 ASDAS remission in 30 (35%)& 55 incr SEC to 300 mg. By wk 24, 22% of 300 mg achieved ASDAS remission; but without signif change in MRI inflamm (SPARCC). Most MRI changes in 1st 4wks https://t.co/pMMtrxxDLh
Dr. John Cush @RheumNow ( View Tweet)
Still's Disease Update
Arthritis Research & Therapy has published an overarching review of Still's disease, claiming it is a single acquired, complex autoinflammatory disease in which both pediatric and adult forms share core pathogenic mechanisms, genetic associations, and https://t.co/8ctddvIq7k
Dr. John Cush @RheumNow ( View Tweet)
Addressing PsA GRAPPA Domains With a JAKi Dr. Schwartzman and Dr. Ruderman discuss the importance of a domain-based approach in PsA management and consider the potential role of a JAK inhibitor. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/u5ThHz2sxo https://t.co/2itTzpCp3b
Dr. John Cush @RheumNow ( View Tweet)
Simulation cost-effectiveness/QOL study compared Rx of psoriasis w/ biologics, phototherapy, or step-therapy Rx. Biologics had best QOL gains; step-therapy Rx similar w/ less variability & lower costs; phototherapy was cost-effective for payors. Pts had highest willingness to pay https://t.co/RyNooKhgQh
Dr. John Cush @RheumNow ( View Tweet)
Gabapentinoid use 2008-2018: worldwide there was an annual incr of +17.2% (from 4.2/d to 18.3/d per 10K pop. Highest gaba use in high income countries, 6X higher than lower income (40/d vs 6.1/d) https://t.co/jXjxNj1Uyz https://t.co/bUhBpaPltc
Dr. John Cush @RheumNow ( View Tweet)
Physician Use of Augmented Intelligence has Doubled
A 2026 Physician Survey assessing AI and its use in Medical Practice has been published and follows earlier surveys on adoption and use. This is the third in a series of longitudinal surveys (prior waves 2023, 2024), enabling https://t.co/4QoMR17Ure
Dr. John Cush @RheumNow ( View Tweet)
Cross-sectional study from UK Clinical Practice Research Datalink Aurum looked at > 40K w/ #PMR Rx w/ steroids - 67% were coprescribed bisphosphonates (BP) & 79% Rx PPIs/H2RAs (less in males & pts deprived areas) resulting more Fx w/in 12 mos (2.32% vs 1.4%). https://t.co/b2DFJMjqCu
Dr. John Cush @RheumNow ( View Tweet)
Adjunctive Prednisolone for Kawasaki Disease
An NEJM study has shown that glucocorticoids provide no added benefit when added to standard primary treatment in Kawasaki disease patients.
Read Article
ACR Backs the Provider Reimbursement Stability Act
ACR
The American College of Rheumatology (ACR) today thanked lawmakers in the U.S. House of Representatives for introducing the bipartisan Provider Reimbursement Stability Act of 2025 (H.R. 8163), legislation designed to stabilize Medicare payments for physicians and protect patient access to care.
Read Article
Retrospective study of 374 newly diagnosed microscopic polyangiitis (MPA) pts - 97 (26%) had severe infections w/in 6 mos - signif higher risk w/ high dose prednisone & chronic lung Dz. most common: bacterial (43%) & lung infx https://t.co/XXAxUZw7kx https://t.co/atK8Ob9zyQ
Dr. John Cush @RheumNow ( View Tweet)
Leeds study of 63 pts w/ palindromic rheumatism (PR) progressed to Persistent IA (PIA) @ median 13.4 mos, hands predominating across flares. PIA developed in joints involved in PR flares in 71% of pts. @RA Dx, PR onset pts had signif higher swollen joints(4.1 vs 3.2) https://t.co/PnrQvWkUm4
Dr. John Cush @RheumNow ( View Tweet)
Modest Benefits with AI Scribes on EHR Documentation
Documenting patient visits in the EHR is essential to care, but a major contributor to clinician burnout. AI-enabled ambient documentation (“AI scribes”) can auto-generate draft clinical notes for clinician review. They may https://t.co/6HaUwpFYLC
Dr. John Cush @RheumNow ( View Tweet)
Retrospective clinicopathologic review of 170 AORTIC surgical pathology cases (2009-16) - showed 87% w/ atherosclerosis, 13% aortitis/periaortitis and 2.4% atherosclerosis w/ excessive inflammation. Lymphoplasmacytic inflammation was most common w/ aortitis/periaortitis. https://t.co/CuP30dqRQU
Dr. John Cush @RheumNow ( View Tweet)
152 pts w/ immune thrombocytopenia (ITP) Rx in DBRPCT of Ianalumab (9mg or 3 mg/kg) or PBO q mo x 4 mos (all on Eltrombopag). Time to Rx failure signif longer w/ ianalumab. Stable 6 month response better w/ 9-mg group vs PBO (62% vs 39%; P=0.045) https://t.co/J04trYAwLu https://t.co/Alm8V2SAXn
Dr. John Cush @RheumNow ( View Tweet)
Litifilimab in Cutaneous Lupus Erythematosus
Biogen has announced positive results of their Phase 2 study, evaluating litifilimab in patients with active cutaneous lupus erythematosus (CLE), presented at the recent American Academy of Dermatology (AAD) Annual Meeting. https://t.co/3Wb6iFViOm
Dr. John Cush @RheumNow ( View Tweet)
Still's Disease Update
Arthritis Research & Therapy has published an overarching review of Still's disease - claiming it to be a single acquired and complex autoinflammatory disease in which both pediatric and adult forms share core pathogenic mechanisms, genetic associations and clinical presentations, with minor differences between children and adults who are afflicted.
Read Article
Physician Use of Augmented Intelligence has Doubled
A 2026 Physician Survey to assess artificial intelligence and its use in Medical Practice has been published and follows earlier surveys around adoption and use. This is the third in a series of longitudinal surveys (prior waves 2023, 2024), enabling meaningful trend analysis. AI adoption has more than doubled in three years and physician sentiment shifting decisively toward cautious optimism.
Read Article
Screening High Risk Myositis Patients for Cancer
An Italian retrospective study of 411 idiopathic inflammatory myopathies (IIM) patients applied IMACS criteria to assess the risk of cancer and found significantly more cancers in those at high risk.
https://t.co/AHvC5xfsCr https://t.co/Bd4VMRX9PU
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
Podcasts
Prescribing Lessons (4.17.2026)-
Top Four and More (4.10.2026)
-
Whats New PsA? (4.3.2026)
PsA GRAPPA Domains- Outcomes With a JAKi
Therapeutic Updates
PsA GRAPPA domains: Outcomes With a JAKi
Sponsored by AbbVie Medical Affairs + Health Impact
Dr. Schwartzman and Dr. Ruderman discuss how PsA disease activity across GRAPPA domains may guide treatment decisions, sharing both the evidence for and their experience with a JAKi across domains.
Read Post
Poster Hall
